Abstracts tagged "Polymyalgia Rheumatica (PMR)"

Abstract Number: 0795 • ACR Convergence 2022
Post-Acute COVID-19 Sequalae (PACS) with New-onset Rheumatological Complications
Neel Thanavala¹, Kiho Son², Nardien Sedhom², Snehal Somalwar³, Zil Patel¹, Rameen Jamil², Carmen Venegas², Ashutosh Thakar², Agnes Yuen⁴, Melanie Kjarsgaard², Susan Waserman², Mylinh Duong², Parameswaran Nair², Christopher Carlsten⁴, Maggie Larche², Terence Ho², Sarah Svenningsen², KONSTANTINOS TSELIOS⁵ and Manali Mukherjee², ¹The Research Institute of St. Joe's Hamilton, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³The Research Institute of St Joe's Hamilton, Hamilton, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵McMaster University, Population Health Research Institute, Hamilton, ON, Canada
Background/Purpose: Post-Acute Sequalae of COVID-19 (PASC), prevalent in ~20-30% of convalescent COVID-19 patients is characterized by new/persistent symptoms after the initial recovery. Certain autoantibodies have…
Abstract Number: 1106 • ACR Convergence 2022
Effect of Tocilizumab on Disease Activity in Patients with Active Polymyalgia Rheumatica on Glucocorticoid Therapy: A Randomized Clinical Trial
Valerie Devauchelle¹, Guillermo CARVAJAL ALEGRIA², Emmanuelle Dernis³, Christophe Richez⁴, Marie Truchetet⁵, Daniel Wendling⁶, ERIC TOUSSIROT⁷, aleth Perdriger⁸, jacques-eric gottenberg⁹, Renaud FELTEN¹⁰, Bruno Fautrel¹¹, laurent chiche¹², Pascal HILLIQUIN¹³, Catherine Le Henaff¹⁴, Benjamin Dervieux¹⁵, Guillaume Direz¹⁶, Isabelle Chary-Valckenaere¹⁷, Divi CORNEC¹⁸, Dewi Guellec¹⁹, Thierry MARHADOUR²⁰, Emmanule Nowak¹⁹ and Alain Saraux²¹, ¹Université de Bretagne Occidentale, Brest, France, ²CHRU de Tours, Tours, France, ³LE MANS general hospital, LE MANS, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Bordeaux University Hospital, Bordeaux, France, ⁶CHU, University Teaching Hospital, Besançon, France, ⁷CHU de Besançon, Besançon, France, ⁸Rennes University, Rennes, France, ⁹Strasbourg University Hospital, Strasbourg, France, ¹⁰Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹¹Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ¹²hopital europeen, Marseille, France, ¹³Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, ¹⁴Morlaix Hospital, Morlaix, France, ¹⁵Mulhouse Hospital, Mulhouse, France, ¹⁶Le Mans Hospital, Le Mans, France, ¹⁷Nancy University Hospital, Vandoeuvre, France, ¹⁸CHRU Brest, Brest, France, ¹⁹Brest University Hospital, Brest, France, ²⁰CHU Cavale Blanche, Brest, France, ²¹CHU Brest, Brest, France
Background/Purpose: Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica (PMR). Interleukin-6 antagonists deserve evaluation in active glucocorticoid-dependent PMR. Our objective was to compare…
Abstract Number: 1107 • ACR Convergence 2022
Efficacy and Safety of Tofacitinib in Patients with Polymyalgia Rheumatica (EAST PMR): A Prospective Study
Xinlei Ma, Fan Yang, Jin Lin and Weiqian Chen, Division of Rheumatology, the First Affiliated Hospital, Zhejiang University School of Medicine, HangZhou, China
Background/Purpose: Polymyalgia Rheumatica (PMR) is a common inflammatory disease in elderly persons whose pathogenesis is unclear. Glucocorticoids are the first-line drugs for patients with PMR,…
Abstract Number: 1543 • ACR Convergence 2022
Resolution of PMR Signs and Symptoms in Patients Treated with Sarilumab: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR) in Relapsing PMR
Robert Spiera¹, Sebastian Unizony², Kenneth J. Warrington³, Jennifer Sloane Lazar⁴, Angeliki Giannelou⁵, Michael C Nivens⁶, Bolanle Akinlade⁵, Wanling Wong⁴, Yong Lin⁴, Frank Buttgereit⁷, Valerie Devauchelle⁸, Andrea Rubbert-Roth⁹ and Bhaskar Dasgupta¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Winchester, MA, ³Mayo Clinic, ROCHESTER, MN, ⁴Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, ⁷Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ⁸Université de Bretagne Occidentale, Brest, France, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ¹⁰Anglia Ruskin University, East Anglia, United Kingdom
Background/Purpose: Sarilumab, a human mAb against the IL-6 receptor α, has been approved in RA and is being investigated for PMR. The SAPHYR study (NCT03600818)…
Abstract Number: 1544 • ACR Convergence 2022
Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica
Justine D'agostino¹, Valerie Devauchelle¹, Guillermo CARVAJAL ALEGRIA², Emmanuelle Dernis³, Christophe Richez⁴, Marie Truchetet⁵, Daniel Wendling⁶, ERIC TOUSSIROT⁷, aleth Perdriger⁸, jacques-eric gottenberg⁹, Renaud FELTEN¹⁰, Bruno Fautrel¹¹, laurent chiche¹², Pascal HILLIQUIN¹³, Catherine Le Henaff¹⁴, Benjamin Dervieux¹⁵, Guillaume Direz¹⁶, Isabelle Chary-Valckenaere¹⁷, Divi CORNEC¹⁸, Dewi Guellec¹⁹, Thierry MARHADOUR²⁰, Aghiles Souki¹⁹, Emmanule Nowak¹⁹ and Alain Saraux²¹, ¹Université de Bretagne Occidentale, Brest, France, ²CHRU de Tours, Tours, France, ³LE MANS general hospital, LE MANS, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Bordeaux University Hospital, Bordeaux, France, ⁶CHU, University Teaching Hospital, Besançon, France, ⁷CHU de Besançon, Besançon, France, ⁸Rennes University, Rennes, France, ⁹Strasbourg University Hospital, Strasbourg, France, ¹⁰Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹¹Pitié Salpêtrière Hospital, Paris, France, ¹²hopital europeen, Marseille, France, ¹³Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, ¹⁴Morlaix Hospital, Morlaix, France, ¹⁵Mulhouse Hospital, Mulhouse, France, ¹⁶Le Mans Hospital, Le Mans, France, ¹⁷Nancy University Hospital, Vandoeuvre, France, ¹⁸CHRU Brest, Brest, France, ¹⁹Brest University Hospital, Brest, France, ²⁰CHU Cavale Blanche, Brest, France, ²¹CHU Brest, Brest, France
Background/Purpose: Today, the only disease activity score developed specifically for polymylagia rheumatica is the PMR-AS. It is a composite index built as an algebraic sum…
Abstract Number: 1545 • ACR Convergence 2022
Increased Neutrophil Activation in Patients with Polymyalgia Rheumatica
Despina Michailidou¹, Linda Johansson², Runa Kuley¹, TING WANG¹, Payton Hermanson¹, Solbritt Rantapää-Dahlqvist² and Christian Lood¹, ¹Division of Rheumatology, University of Washington, Seattle, WA, ²Department of Public Health and Clinical Medicine, Rheumatology, Umeå University, Umeå, Sweden
Background/Purpose: Neutrophils are important in host defense. However, neutrophil activation has also been involved in the immunopathogenesis of several autoimmune diseases due to their many…
Abstract Number: 1546 • ACR Convergence 2022
Treatment of Polymyalgia Rheumatica by Rheumatology Providers: Results from the ACR Rheumatology Informatics System for Effectiveness Registry
Sebastian Sattui¹, Zihan Wan², Fenglong Xie², Cassie Clinton², Robyn Domsic¹ and Jeffrey Curtis³, ¹University of Pittsburgh, Pittsburgh, PA, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Polymyalgia rheumatica (PMR) is one of the most common systemic rheumatic diseases in older adults. Glucocorticoids (GC) remain the main treatment, and although recommendations…
Abstract Number: 1547 • ACR Convergence 2022
Effectiveness of Interleukin-6 Receptor Inhibitors for Polymyalgia Rheumatica
Jeffrey Curtis¹, Kerri Ford², Stefano Fiore³, Danielle Isaman⁴, Lita Araujo⁵, Natalia Petruski-Ivleva⁶ and Fenglong Xie⁷, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Sanofi, Destin, FL, ³Sanofi, Bridgewater, NJ, ⁴Sanofi, Chapel Hill, NC, ⁵Sanofi, Cambridge, MA, ⁶Sanofi, Unknown, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Interleukin-6 receptor (IL-6R) inhibition has been shown to be effective in giant cell arteritis but data are limited in polymyalgia rheumatica (PMR). We conducted…
Abstract Number: 1548 • ACR Convergence 2022
Immune Cells Are Highly Disturbed in Polymyalgia Rheumatica Patients
Guillermo CARVAJAL ALEGRIA¹, Sara Boukhlal², Sophie Hillion³, Pierre Pochard³, Emmanuelle Porchet³, Alain Saraux⁴, sandrine jousse joulin⁵, Thierry MARHADOUR⁶, Dewi Guellec³, Divi CORNEC⁷ and Valerie Devauchelle², ¹CHRU de Tours, Tours, France, ²Université de Bretagne Occidentale, Brest, France, ³CHRU de Brest, Brest, France, ⁴CHU Brest, Brest, France, ⁵Roche, Brest, France, ⁶CHU Cavale Blanche, Brest, France, ⁷CHRU Brest, Brest, France
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease. But it's pathophysiology and the impact of the treatments on immune cells are poorly known. Our objectives…
Abstract Number: 1619 • ACR Convergence 2022
Silent Giant Cell Arteritis in Patients with Polymyalgia Rheumatica: Characteristics and Peculiarities
Eugenio De Miguel¹, PIERLUIGI MACCHIONI², Edoardo Conticini³, Corrado Campochiaro⁴, Rositsa Karalilova⁵, Sara Monti⁶, Cristina Ponte⁷, Giulia Klinowski², Irene Monjo⁸, Paolo Paolo Falsetti³, Anastas Batalov⁹, alessandro tomelleri⁴ and Alojzija Hocevar¹⁰, ¹Hospital Universitario La Paz, Madrid, Spain, ²IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ³Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁴IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, ⁵Medical University of Plovdiv, University Hospital Kaspela, Plovdiv, Bulgaria, ⁶Rheumatology, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italy, ⁷Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte EPE, Lisboa, Portugal, ⁸Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ⁹Medical University of Plovdiv, Plovdiv, Bulgaria, ¹⁰University Medical Centre Ljubljana, Ljubljana, Slovenia
Background/Purpose: Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) are closely related diseases. PMR occurs in approximately 50 % of patients with GCA. In a…
Abstract Number: 1676 • ACR Convergence 2022
Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Robert Spiera¹, Sebastian Unizony², Kenneth J. Warrington³, Jennifer Sloane Lazar⁴, Angeliki Giannelou⁵, Michael C Nivens⁶, Bolanle Akinlade⁵, Wanling Wong⁴, Yong Lin⁴, Frank Buttgereit⁷, Valerie Devauchelle⁸, Andrea Rubbert-Roth⁹ and Bhaskar Dasgupta¹⁰, ¹Hospital for Special Surgery, New York, NY, ²Massachusetts General Hospital, Winchester, MA, ³Mayo Clinic, ROCHESTER, MN, ⁴Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Regeneron Pharmaceuticals, Inc., Tarrytown, NY, NY, ⁷Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany, ⁸Université de Bretagne Occidentale, Brest, France, ⁹Division of Rheumatology, Cantonal Clinic St Gallen, St.Gallen, Switzerland, ¹⁰Anglia Ruskin University, East Anglia, United Kingdom
Background/Purpose: IL-6 is elevated in patients with active PMR and is associated with disease activity, relapse and severity. Clinical trials with IL-6 receptor (IL-6R) inhibitors…
Abstract Number: 1835 • ACR Convergence 2022
Clinical Features of Patients with Sarcoidosis and Concomitant Connective Tissue Disease
Magdalena Harasimowicz¹, Emily GIlbert², Sarah Yi³ and Rochella Ostrowski⁴, ¹Loyola University Medical Center Department of Internal Medicine, Chicago, IL, ²Loyola University Medical Center Division of Pulmonary and Critical Care Medicine, Maywood, IL, ³Loyola University Stritch School of Medicine, Maywood, IL, ⁴Loyola University Medical Center Division of Rheumatology, Maywood, IL
Background/Purpose: Sarcoidosis is a multiorgan granulomatous disease with a prevalence of 60 per 100,000 in the United States.1 Given the low prevalence of both sarcoidosis…
Abstract Number: 0204 • ACR Convergence 2022
Persistence of Fatigue, Sleep Disturbance and Mood Disorders in PMR Patients Despite Standard Treatment
Jessica Leung¹, Claire Owen², David Liew³ and Russell Buchanan³, ¹Austin Health, Preston, Victoria, Australia, ²Austin Health, Malvern East, Australia, ³Austin Health, Heidelberg, Australia
Background/Purpose: Polymyalgia rheumatica (PMR) is typified by pain and stiffness of the shoulder and hip girdles. Previous qualitative studies have highlighted the importance to patients…
Abstract Number: 1843 • ACR Convergence 2022
Trends in the Cumulative Exposure to Corticosteroids in Polymyalgia Rheumatica (PMR) Patients: A Single Academic Center Experience
Vivekanand Tiwari¹, Vishnuteja Devalla², Emily Campbell¹ and William Rigby¹, ¹Dartmouth Hitchcock Medical Center, Lebanon, NH, ²Essential Health St. Joseph's-Brainerd Clinic, Brainerd, MN
Background/Purpose: Polymyalgia rheumatica (PMR) treatment is predominantly based on long-term corticosteroids, which results in significant corticosteroid-related toxicities. Studies1,2 have shown patients with PMR are exposed…
Abstract Number: 0478 • ACR Convergence 2022
Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR
Colm Kirby¹, Rachael Flood¹, Ronan Mullan¹, Grainne Murphy² and David Kane¹, ¹Tallaght University Hospital, Dublin, Ireland, ²Cork University Hospital, Cork, Ireland
Background/Purpose: It has been reported that 20-50% of patients with PMR have subclinical GCA. The natural history of US-defined subclinical GCA in PMR is not…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].